dc.contributor.author | Mencel, J | |
dc.contributor.author | Slater, S | |
dc.contributor.author | Cartwright, E | |
dc.contributor.author | Starling, N | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2022-12-23T10:03:06Z | |
dc.date.available | 2022-12-23T10:03:06Z | |
dc.date.issued | 2022-10-18 | |
dc.identifier | ARTN 5105 | |
dc.identifier | cancers14205105 | |
dc.identifier.citation | Cancers, 2022, 14 (20), pp. 5105 - | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5627 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.doi | 10.3390/cancers14205105 | |
dc.description.abstract | Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural genomic landscape compared to tissue-based next-generation DNA sequencing (NGS). In addition, ctDNA can potentially overcome the challenges of tumour heterogeneity seen with tissue-based NGS. Although the evidence for ctDNA in GC is evolving, its potential utility is far reaching and may shape the management of this disease in the future. This article will review the current and future applications of ctDNA in GC. | |
dc.format | Electronic | |
dc.format.extent | 5105 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | MDPI | |
dc.relation.ispartof | Cancers | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | ctDNA | |
dc.subject | gastric cancer | |
dc.subject | liquid biopsy | |
dc.title | The Role of ctDNA in Gastric Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-10-13 | |
dc.date.updated | 2022-12-23T10:02:35Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.3390/cancers14205105 | |
rioxxterms.licenseref.startdate | 2022-10-18 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36291888 | |
pubs.issue | 20 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/cancers14205105 | |
pubs.volume | 14 | |
dc.contributor.icrauthor | Slater, Susanna | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Prof Kevin Harrington) on 2022-12-23. Deposit type is initial. No. of files: 1. Files: cancers-14-05105-v2.pdf | |